Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients
Int. Journal of Clinical Pharmacology and Therapeutics · 2023
DOI: 10.5414/cp204347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2023. Verfasst von Zhongfeng Dang und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Dang, Z., Jiang, L., & Huang, F. (2023). Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204347
Vancouver
Dang Z, Jiang L, Huang F. Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients. Int. Journal of Clinical Pharmacology and Therapeutics. 2023. doi:10.5414/cp204347
BibTeX
@article{Dang2023,
author = {Dang, Zhongfeng and Jiang, Liwen and Huang, Fengping},
title = {Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2023},
doi = {10.5414/cp204347}
}
EUVIMED